Citation from the patent:

Well, I agree that I'm not all too happy with the terms of the convertible notes guaranteeing a 65% discount from the stock price which is going to act as liquidation and pressure the stock price as they are converted into shares.

But one thing is clear from the agreements of C and T Ichim, they expect something concrete from their research within the next 18 months as the majority of their potential worth in tied up in the "signing bonus" shares they agreed to which are contingent on specific milestones being reached and which are completely lost if the progressive steps to clinical trials are not reached. I don't think you'd sign over your patent rights, which you purchased through private arrangements, to Mr. Koos in return for "worthless shares" that you will indeed lose, i.e. lose your patent and any future income from shares you received for your patent unless you fully expected real and concrete development of that patent with the next 1.5 years, would you?

Would a scientist that has spent years of his life researching a specific treatment, co-patents the treatment and then buys out the other person to retain full rights of the patent then just give that patent over to an unsuccessful business man in return for potential shares that you only get if your treatment goes forward, is successful and proceeds to clinical trials against a deadline of 18 months, if you didn't believe the pieces were in place for success?

8K says Regen paid $9,000 plus 1,000,000 shares of RGBP series A preferred stock for the patent. Series A preferred are not tradable at this time, so obviously, Ichim believes they will have value in the future or he just gave up a large part of his life for $9,000.

Elements of Scenarios 2-3-4 with a possible buildup to a modified Scenario 5 including a US partnership in mid to late 2015 now possible.

I'm glad for a couple points today, first, we received a PR early in the morning as hoped for to clarify a little what has been going on behind the scenes as reasons for the recent hiring and divvy developments.

Reading between the lines, to go from basically bankrupt (i.e. no money in bank on Sept 30, 2014) to a statement of over $700,000 raised by "angel investors" is very good news and along with employees on salaries means that they expect to have cash to pay for things in the near future. THIS alone, is a major change from the status of having to issue hundreds of thousands to millions of shares of stock (i.e. BMSN) in the past to pay for any little development. Looking for upcoming financials to verify cash money in the bank which alone removes the threat of any immediate dilution to stay afloat. Something we faced daily in the past. Check one improvement.

Secondly, the PR is not the golden pot at the end of the rainbow that some may have expected, but at least this PR has a more straightforward and clear statement of recent events. We have $700,000 raised, a new patent, eye on parallel development, validation I believe that NR2F6 is now possibly the main focus because is can provide CURES, not just treatments of more than one cancer if successful because it attacks the stem cells needed by the cancer to grow. The future treatment(s) might be a combination of NR2F6, the new patent just announced for CTCFL and a combination of dCellVax, I don't know, but in the past 2 months, RGBP has added 2 patents from the Ichims that are aligned with previous goals, so that is a plus since those who developed the patents are now employees. (Remember the previous scenario was Koos owned patents with no direct employees to develop them other than an arrangement with Wei Ping Min who seems to be working for many with his research team.

Having Ichims in house full time is a game changer for more timely development which means more timely news which in turn creates more interest and gives RGBP more potential and as previously stated, it has changed dramatically on paper from a "shadowy" Koos to 2 patented, award winning scientists as employees and directors with Koos as CEO and Cavens selling the IP potential to interested parties. Check off major positive development number 2.

PR leaves open to speculation what the near future for NR2F6, dCellVax and HemaX is in regarding RGBP guiding development, partnering or if they can prove with more data the potential efficacy of a treatment and file a new IND, the chance of selling or being bought out by bigger fish, but all 3 of these scenarios have more chance of success now that there is money in the bank and two scientists on board.

Now, we can expect that if more shares are issued, it will only occur to fund clinical trials in conjunction with FDA approval instead of in order to pay ENTB $2,000 rent.

That is all positive news today, even if RGBP trades between .20 and .40 for the next 2 months, or until the next PR. I'm looking forward to regular monthly, bi-monthly updates from now on.

Strange morning. L2 looking weird with .19 bid and .32 ask and no NITE on either side.

Don't know exactly what this means, whether there are technical issues here or whether something else is up.

Thx. Got it.

Well, I realize what Ex-Dividend means, but t the article states that RGBP will not be quoted ex-dividend, so there is not an ex-dividend date it seems to make calculations by. Wondering why it specifically states that RGBP will not be quoted ex-dividend. Didn't know if that meant something special...

Just curious, as I'm waiting for next PR to decide what to do.

What does: "Will not be quoted ex dividend" mean?

We are in sync. Selling 8 million shares for .25-.30 and bringing in 2-2.4 Million dollars while retaining share control as well as voting control is definitely a scenario I was thinking about.

Of course they could sell even less and have the financing to get through the next year which hopefully would put these treatments well on the course of human clinical trials and if those trials prove positive as we expect, they would not have any worry about raising more financing.

Yes, thanks.
Reading through parts of this, I'm not sure what to deduce as I am not a medical expert. Seems to apply at least to HemaX as " Hematopoietic stem/progenitor cells derived from peripheral and cord blood " is mentioned. Whether this is part of the FDA safety protocol delay or not is now unclear as it says it is not legally binding. But since FDA has final say in review of anything for approval, it's probably kind of "binding", isn't it?



Another quote from final section:


One way or another, we should receive one or more PRs in the next few weeks that will tell us whether we've been believing in fairy tales or whether our hope is finally seeing some advance fruition

A while back GM posted a link to the FDA that dealt with new rules regarding cell based drugs in development.

If GM could repost and someone do research with comment on how they believe this affects HemaX, cCellVax and NR2F6 timing development, that would be of benefit to all to know.

I forget what the timeframe was, if any given, for when the FDA was expected to finalize and publish them.

I think the answer to this is simple and I've posted as such:

If we do not here of anything significant by the end of March or Mid-April, I believe the share price of RGBP will have sunk back to the .12 range.

I don't think the run up is so much because of preferred A Shares and the hope of a .01 divvy (that isn't even certain since it has not been declared but only stated "in the event of a declaration").

My belief and reason for hope as I have stated repeatedly is in the connection of the events and PRs over the past few months that point to the development of NR2F6 target for ending leukemic cells and the hiring of the Ichims and Cavens as a development that make be even more significant than HemaX and dCellVax because of its potential efficacy and the exposure C. Ichim received at the ASH conference.

HemaX and dCellVax, as far as we know have been delayed because the safety trials did not meet FDA standards of GLP and so, while promising, might be weeks to months away, depending on various factors and the FDA's on development of new rules regarding cell based treatments. All this has been stated and posted.

But if international or national interest in NR2F6 is solid as a possible CURE for Leukemia, there is more than one rich person out there with a personal friend or child suffering from this cancer that may be more than willing to put a million dollars or more into this research and give RGBP the financial backing it needs to go into high gear and fast track its development, in which case, you can say goodbye to the .10s, .20s and .30s from the rear view mirror.

This alone, some type of financial backing, partnership that is not the burden of a loan hanging over the company, in my opinion, will rapidly increase our value. But the development of the treatments, I have always stated, will take time. (More in the US than elsewhere should a foreign partner come on board.)

I hope it is better than this agreement. Per my recollection, this funding agreement was to expire 12 months from the original date or April 2013, so the original agreement has expired.

The funding was needed to proceed to the expense of clinical human trials, which up to this point, RGBP has not arrived at.

Plus, this funding is basically a line of credit which incurs accrued interest, hardly a way to fund a divvy (although I don't see the divvy as an immediate focus).

My hope is for cash for shares or cash for partnership or cash to buy foreign rights that in turn can come back to help USA development.

Thx CT. Now let's hope scenario 3 or higher plays out soon!

I'm hoping for a PR that reveals the reasons of this divvy next week, but if I have to wait a little longer, so be it. Anything that avoids a 2 month silence will be great I think.

True, as a theoretical scenario, you can add it and until approval for clinical trials is given, it can be defended as plausible.

However, if it was all smoke and mirrors, they could not have stated that the FDA had reviewed and approved HemaXellerate I for manufacturing and trial protocols.

If it was all creative vocabulary, you would have to imagine C. Ichim as a made up fantasy and therefore promote a conspiracy theory that she never studied at Univ of Toronto, never received an award, never skated across Canada, never was in a lab and never had a mother she lost to leukemia. One would have to propose that Koos somehow paid off the Canadian newspapers and news stations to create all thing phony background scenarios so that he could scam people on a penny stock exchange somehow.


Hmmmm, is scenario 7 the most plausible? One must take some time to reflect. And one must wonder, why does someone spend so much time posting to a stock forum to discourage others from owning a penny stock that clearly he must not own or he would be living in complete dissension within himself. What would your theory be so such a person?

Adding another possible scenario to previous posting not as yet mentioned specifically.

Is 2015 a New Case for Hope?

Decided to go back and reread 2015 PRs to see if I could piece together a valid case for hope and that the buzz and buildup to divvy date does not end up the same as the RGBP spinoff (that was supposed to be above a dollar, remember?)

Here's about the best case scenario I can build that is not complete fantasy:
[First, everyone should read this article giving some personal background on Dr. Christine Ichim because I think she is now a major player in what is taking place, posted back in Dec by 1-eye-jack (interestingly enough): Why Dr Thomas Ichim and sister Dr. Christine Ichim are so motivated ].

Jan 8, 2015 PR mentions 2nd Generation of gene silencing drug candidate directed at NR2F6, a treatment that leads cancer cells to change into non cancerous cells: "The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer. "Given that Regen BioPharma is already clinically developing gene-silencing therapeutics in its IND for dCellVax, we anticipate substantial synergy of these programs."

Jan 14, 2015 PR giving overview of 2015 priorities talks first about this new treatment candidate (not dCellVax or HemaX), then mentions dCellVax and says HemaXellerate protocols are still under review by FDA for conducting an additional GLP safety study.

Jan 22, 2015 PR - One week later we have the 8K filed to hire both Ichims (Thomas and Christine) with monthly salary and stock (even though RGBP doesn't have the cash). Ergo, I see another confirmation that NR2F6 is now the main focus since its small molecule inhibitors and such have proved effective in similar clinical treatments for a different cancer at success rates over 80% cfr notation in Jan 14th PR. And Christine is the person who has been working and developing this treatment. (Previously she was working on cancer cure for dogs under Entest, so to move her into RGBP and purchase her treatment patents is a clear new direction for RGBP.

Feb 9, 2015 8K tells us RGBP issues promissory Note for $50,000 (not a huge amount, but enough to cover new salaries for a couple months).

Feb 13, 2015 A few days later Todd Caven becomes CFO (whose background is supposed to be in securing funds / mergers).

Feb 17, 2015 Another 8K confirming the issuance of shares to all new hires.

Feb 24, 2015 PR to comment on Flexus buyout as validation of RGBP's own patents and treatments in development. Trying to generate interest of investors and money needed to develop - i.e. Todd Cavens job.

Feb 24, 2015 PR Piggy back PR stating issuance of dividend to shareholders of March 10 of Series A preferred (voting value and future dividend value)


So what to make of these many PRs in succession after our usual long periods of silence? Here are possible scenarios:

1. Worst case - annual bluff to drive up price at least for a few days if Koos and Company have a scam to make money by shorting it or somehow else where SEC does not see it. (Conspiracy theorists and basher bait)

2. Company has been rather stagnated and hoping new hires and people will help to start bringing the company forward. (No major news around the corner, just starting the process of regular updates to act like a real business)

3. RGBP is about to turn the corner with the new NR2F6 breakthrough and has had interest and guarantees of some kind of partnership to fund not only NR2F6, but advance dCellVax and HemaX as well.

4.Most probable: (Why the hiring and divy all at once?) RGBP is out of cash and needs cash to conduct GLP as well as future clinical trials. With NR2F6 2nd Generation strength concept proven in vitro, RGBP sees great potential and wants to develope it quickly, so they believe timing is right (Feb seems to be the historic month for moves up) to raise funds. Therefore, T&C Ichim are formal hires, Caven comes on to direct raising funds and I think the divvy as others mentioned is to boost price from .10 to over .50, clear out any mishandling of shares trading and then RGBP announces a sale of 20M-50M shares somewhere between .30-.50 which will raise 6M-25M in cash. Think about it, who on this board wouldn't think the company would be better situated with 6-25 million in cash, 3 possible candidates in the pipeline and a 100 M share O/S? Stock wouldn't stay at .30 even if investors shares were sold that low. Suddenly, RGBP would appear on paper and to others as a legit company with cash and potential instead of the one man show it has been.

5. International JV/Partnership to explore development of NR2F6 target (plus HemaX I and dCellVax) that moves forward without need of FDA approval because it would be an exclusive rights application for foreign areas only. Unless we get news that FDA has approved safety testing protocols for HemaX and dCellVax, or better, that they have and tests have been underway with positive results to date (a slim possibility), all 3 products are on hold until FDA finalizes its standards for cell safety judging. However, given C. Ichim's presentation in Jan at ASH with over 100 countries represented, it is possible that an international entity wants to partner/license/buy out the IP for development elsewhere, leaving all US rights still in the hands of RGBP, but allowing the research and human trials to go forward elsewhere, which if successful, would build interest and buyout of RGBP in US for the future.

6. BEST case scenario: RGBP has finally received word that HemaX protocol for safety trials will be approved, dCellVax will also get Green Light and the development of NR2F6 is so positive, that they are positioning themselves against an outright takeover and setting structure for an advantageous partnership once the news of these 3 developments all hit at once.


I don't know which is the more probable, but I think the recent actions are more focused on NR2F6 holding the brightest future of development and buyout possibilities than either HemaX or dCellVax at this time.

AIMO

Another major cancer treatment buyout in billions.

Now, let me say up front, I'm not saying RGBP compares to Pharmacyclics which has hundreds of millions in revenue on their drug treatment already, but the fact that the cancer treatment sector seems to have heated up with major purchasing going on is certainly on the encouraging side.

http://finance.yahoo.com/video/abbvie-buys-pharmacyclics-21b-deal-133000380.html

This action certainly doesn't hurt. Once we get past the FDA safety protocol approvals, things can develop very quickly, very nicely. My time frame for clarity is from 2-6 weeks. By mid April, I think RGBP will have released enough PRs to give us a lot better knowledge of where things are at.

No wonder Bristol Myers is going buy happy:

http://blogs.barrons.com/stockstowatchtoday/2015/03/04/bristol-myers-squibb-this-is-the-fastest-approval-ive-seen/?mod=yahoobarrons&ru=yahoo

Well, for you chart traders, we've closed the gap, covered the 50% Fibonacci retracement and at least for the last hour or so, the heavy selling has all but dried up. If we hold here, with only a 12% loss on the day and almost 200% gain from a week ago, I won't complain.

I agree that at some point it makes sense that there has to be a mechanism for buy back of BMSN, if only so that Koos can liquidate his 60,000,000 shares I believe he has.

As has been pointed out mulitiple times in the past, while the focus and deals will be with RGBP, as long as BMSN maintains majority share holder in RGBP, the value of RGBP rising will also affect BMSN (ENTB I'm less convinced other than for DT activity).

I don't think that happens all at once. I think the BMSN share buy back comes further down the line, but I fully agree that the deal coming has to do with input of cash into the scenario to facilitate and secure that development is forthcoming without having to rely on piecemeal dilution on happenstance at current trade pricing. I think it comes in a big chunk (5-10 million shares) which generates several million dollars and we go from there.

Even .01 on 52,000,000 shares is $520,000 or over $2M/yr in dividends so that set up is either a very tall tale vis a vis the current situation or something much bigger is at least envisioned at this point. Until it happens, it's only theory and we've all had our fill of theories.

This is either the starting point towards real success of the grand finale of fireworks after which the game is over because if this is not real, but a PR trick, no one will believe in this again. My bet is on the former, not the latter, as I've said, with C. Ichim's salary and stock deal my main cause for hope.

In between watching the ticks of trading, read this to get an idea of the person behind the science and how dedicated Dr. C. Ichim is:

http://s.webry.info/sp/blading.at.webry.info/200610/article_8.html

Agreed. Signs are that something is moving forward and changing.

It might not be "to da moon" all at once, but any concrete developments that assure stability and progress will change the dynamics here.

I'd be happy with an announcement at end of March that they have lined up 5 investors to buy a couple million shares each and so put significant cash in the coffers to guarantee any R&D over the next 2-3 years. Heck, they could even use some of it to build a new GLP lab. Anything on this level or better will clearly change the tone of the company on paper and in reality. As of now, we have mainly been left to guessing.

Thanks Traz. For now, the hope has been rekindled and it will either prove fruitful or failure within the next 4-8 weeks is my gut feeling.

To me, the spinoff of RGBP was done in true anticipation of HemaXellerate I being approved for clinical trials with dCellVax on its tails. When HemaXellerate was turned down for further safety testing and no immediate protocol resolution was announced (Remember last year's PR on phone conversation with the FDA that lead to the new safety protocols submitted, but long overdue for approval - I now believe due to the FDA revision of the rules - as linked to by GM), the wind dropped out of RGBP's sails and we have bourne the brunt of the price fallout. Then they announced dCellVax would face a similar timeframe for development, i.e. they knew it would face similar cell safety test protocol most likely and therefore not be ready for immediate approval to clinical trials.

I had resolved to giving up hope based on Koos working on his own doomed to always being behind what others would soon develop.

As you have seen by my posts, this has changed with the overall picture and developments pertaining to the Ichims and something very specific, and its not some dreamed about future ebola cure, but the very specific NR2F6 treatment that didn't come from a lab last week, but is fruit of the eleven years (I believe) pursuit of a cure for leukemia by C. Ichim after she lost her mother to the same disease. There's nothing like a motivated woman and I truly hope that such a woman would not be a fool to sign her research and patents over to a company with no money unless there was some other factors involved that guaranteed her pretty much success and reward.

To that, I look at her contract: the salary is mediocre for an advanced scientist with a possible cure ($6K/month), but I believe she has 6 million shares of RGBP that invest only upon success, so she's not working for $52K/yr, but on the possibility of millions as reward for her patent development. She moved from animal cancer treatments for Koos with ENTB without a structure for treating animals when Koos lost the veterinary practice to now focusing on humans with pre-stage leukemia and leukemia. My current bet is on her being successful enough to draw in outside money to give her a chance and she was exposed to outside money in January at the ASH with follow up PRs in steady fashion leading up to something becoming more clear to us after March 10th.

Whatever that is I believe we will know before the end of March or by mid-April and I can wait now with hope. If we get to May without any significant news, then I'll give the weight of evidence back to this all being another early year PR trick, but I think with C. Ichim and her brothers as employees, this year is different because Koos will be dealing with them first and investors only second.

Pax et bonum.

Dave, I agree it's possible that HemaXellerate could be further along, but let's reflect on whether it makes sense to believe that is the current catalyst or not.

1. As of Jan 14th, safety protocols have not been approved and we know that the FDA regulations surrounding cell treatments and the safety requirements are in development in draft form. (What are the chances that in the midst of this the FDA has given RGBP approval to go forward with safety tests that might not meet its final standards when RGBP already conducted safety trials that the FDA rejected for not meeting its safety standards?

2. Furthermore, what is the likelihood that RGBP received approval and conducted safety tests without issuing a press release or trying to build anticipation that HemaX was on its way to clinical trial approval?

3. Why, when Wei-Ping Min was the one overseeing the development, would they make a big PR about hiring C. Ichim and her patents, but not mention HemaX if the big news coming is HemaX approval?

I could go on. My thought is that recent activity is not built or focused on secret trials of HemaXellerate I coming to fruition unless you believe this company just likes surprising the investors, both with good and bad news. I follow the smoke to the fire and all the smoke recently announced has focused on C. Ichim and the developments she is responsible for. The last news on HemaX was it was on hold with no timeframe to anticipate. All the recent hirings and PRs point to a "new development" that has synergistic energy with the HemaX and dCellVax already in treatment and that is NR2F6 which is not a lone cancer target, but the process of attacking the stem cell development of this target can be applied to more than one cause. Hence, it's value is beyond the already several billion dollar treatment for myleo....

That's where I'm coming from. If HemaX was about to take center stage, it wouldn't make sense to make the buildup to the news focused on something else in my opinion.

So, do you believe the company has outright lied to us when it recently said that they submitted protocols for the safety trial and that this was still under review by the FDA?

Do you think the company would put us on notice that HemaX clinical trials were not imminent (note GM's post on FDA cell trial rules under development) only to then release news that HemaX is approved for clinical trials?

I'm sorry, but that doesn't make sense or mess with what we know.

While I initially thought this PR was mostly fluff, except for the fact that she was allowed to present - THAT's not fluff, I didn't pay much attention to the "well received.... follow up interest".

Well, the handing over of her research to RGBP in return for shares and a very modest salary AND the fact that her shares invest according to milestones reached and there is an 18 month time frame on paper to me NOW means that indeed, something very significant may be in line. My confidence in not in Koos, but in the Ichims with salaries and full time consideration of moving these treatments forward along with someone other than Koos (Cavens) able to dedicate his time to making deals I definitely feel that some type of concrete deal will be announced by end of March or April that will be a long term game changer for RGBP and possibly put it on the Pharaceutical map.

But even if RGBP was bought out tomorrow, it doesn't mean any drug will be approved next week, so let's keep the drug pipeline and development real in terms of time it takes. Even a licensing of the NR2F6 to a large pharma would change the scenery for RGBP.

I again have hope of recuperating my losses.

WHY? The latest PR confirms previous PRs that HemaX protocols for a safety test that is needed to be completed before FDA approval is still under review. The protocols are under review. After they are approved we are looking at most likely 2-3 months before approval.

Let's stick to the facts of what we know. We know they've hired the Ichims and Caven and took out a loan to only cover a couple months salary. We are finally getting a steady diet of PRs with updates and seemingly good news. I don't see HemaX as the immediate factor or catalyst at the moment. HemaX right now is a future bonus as I believe NR2F6 target treatment is the key.

I will make another post with a couple quotes people may have missed that now seem to be coming to light.

2 pieces to the puzzle I believe:
1. Low float for penny stock and most longs entered at much higher prices in BMSN that created the RGBP divvy shares that started at .50, so we don't want to sell just as it's getting back its feet.

2. With divvy date coming, most want in, not out. The low volume means this is not yet the target of DT or a pump and dump. This to me is sign of actual real growth and traction.

I need to get to or over $1.00 to make up for heavy losses here and elsewhere. That's my goal for shares trading (other shares in Roth can grow the next 15 years.)

Confirmation. Thanks CT

This CV shows that Dr. C. Ichim has been uniquely focused on the NR2F6 target for the past 10+ years. This confirms my gut and in between the lines reading of the past PRs that the recent activity I believe is focused on NR2F6 discoveries and the success of generating in vitro a 2nd Generation cellular treatment. This was her talk at the recent Hema conference where it seems she got in last second and the subsequent PR stated that it generated a lot of interest (grain of salt).

The fact of the Ichims hire by RGBP with no money at the time, then the subsequent $50K promissory note and divvy surely means a transition to real development is anticipated by RGBP to take place within a short time frame, let's say 2-3 months with the Ichims working full time as employees.

What that will be (sale of new stock to investors to raise funds for research or partnership arrangement) is unknown, but I'm again walking with hope that this is not a smoke screen and something concrete will come of it.

I think GM's post that the FDA is undergoing regulatory protocol changes in the field of cellular treatments is the reason that HemaX is still "under review", as the FDA wants to finish their rules before signing off on RGBP's protocol for safety study of HemaX (and possibly dCellVax).

But NR2F6 might be the game changer here in light of the 1.2 billion buyout of Flexus by a large bio-pharma in order to acquire the rights and intellectual property of similar cell treatments that aren't even in clinical trials yet. That fact and the fact C. Ichim has multi patents and 10 years of study/research on NR2F6 now weighs more than Koos' incompetence in the field.

Let the Ichims roll!

And they updated Intellectual property page:

Worth a look:
http://www.regenbiopharma.com/intellectual-property.html

Adding one more probable scenario in BOLD below to my previous post. And I think it is the most probable and still good news for longs.

Is 2015 a New Case for Hope?

Decided to go back and reread 2015 PRs to see if I could piece together a valid case for hope and that the buzz and buildup to divvy date does not end up the same as the RGBP spinoff (that was supposed to be above a dollar, remember?) And it is encouraging to see that price is sustaining and growing after last PR - could it be this it not another false alarm?

Here's about the best case scenario I can build that is not complete fantasy:
[First, everyone should read this article giving some personal background on Dr. Christine Ichim because I think she is now a major player in what is taking place, posted back in Dec by 1-eye-jack (interestingly enough): Why Dr Thomas Ichim and sister Dr. Christine Ichim are so motivated ].

Jan 8, 2015 PR mentions 2nd Generation of gene silencing drug candidate directed at NR2F6, a treatment that leads cancer cells to change into non cancerous cells: "The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer. "Given that Regen BioPharma is already clinically developing gene-silencing therapeutics in its IND for dCellVax, we anticipate substantial synergy of these programs."

Jan 14, 2015 PR giving overview of 2015 priorities talks first about this new treatment candidate (not dCellVax or HemaX), then mentions dCellVax and says HemaXellerate protocols are still under review by FDA for conducting an additional GLP safety study.

Jan 22, 2015 PR - One week later we have the 8K filed to hire both Ichims (Thomas and Christine) with monthly salary and stock (even though RGBP doesn't have the cash). Ergo, I see another confirmation that NR2F6 is now the main focus since its small molecule inhibitors and such have proved effective in similar clinical treatments for a different cancer at success rates over 80% cfr notation in Jan 14th PR. And Christine is the person who has been working and developing this treatment. (Previously she was working on cancer cure for dogs under Entest, so to move her into RGBP and purchase her treatment patents is a clear new direction for RGBP.

Feb 9, 2015 8K tells us RGBP issues promissory Note for $50,000 (not a huge amount, but enough to cover new salaries for a couple months).

Feb 13, 2015 A few days later Todd Caven becomes CFO (whose background is supposed to be in securing funds / mergers).

Feb 17, 2015 Another 8K confirming the issuance of shares to all new hires.

Feb 24, 2015 PR to comment on Flexus buyout as validation of RGBP's own patents and treatments in development. Trying to generate interest of investors and money needed to develop - i.e. Todd Cavens job.

Feb 24, 2015 PR Piggy back PR stating issuance of dividend to shareholders of March 10 of Series A preferred (voting value and future dividend value)


So what to make of these many PRs in succession after our usual long periods of silence? Here are possible scenarios:

1. Worst case - annual bluff to drive up price at least for a few days if Koos and Company have a scam to make money by shorting it or somehow else where SEC does not see it. (Conspiracy theorists and basher bait)

2. Company has been rather stagnated and hoping new hires and people will help to start bringing the company forward. (No major news around the corner, just starting the process of regular updates to act like a real business)

3. RGBP is about to turn the corner with the new NR2F6 breakthrough and has had interest and guarantees of some kind of partnership to fund not only NR2F6, but advance dCellVax and HemaX as well.

4.Most probable: (Why the hiring and divy all at once?) RGBP is out of cash and needs cash to conduct GLP as well as future clinical trials. With NR2F6 2nd Generation strength concept proven in vitro, RGBP sees great potential and wants to develope it quickly, so they believe timing is right (Feb seems to be the historic month for moves up) to raise funds. Therefore, T&C Ichim are formal hires, Caven comes on to direct raising funds and I think the divvy as others mentioned is to boost price from .10 to over .50, clear out any mishandling of shares trading and then RGBP announces a sale of 20M-50M shares somewhere between .30-.50 which will raise 6M-25M in cash. Think about it, who on this board wouldn't think the company would be better situated with 6-25 million in cash, 3 possible candidates in the pipeline and a 100 M share O/S? Stock wouldn't stay at .30 even if investors shares were sold that low. Suddenly, RGBP would appear on paper and to others as a legit company with cash and potential instead of the one man show it has been.

5. BEST case scenario: RGBP has finally received word that HemaX protocol for safety trials will be approved, dCellVax will also get Green Light and the development of NR2F6 is so positive, that they are positioning themselves against an outright takeover and setting structure for an advantageous partnership once the news of these 3 developments all hit at once.


I don't know which is the more probable, but I think the recent actions are more focused on NR2F6 holding the brightest future of development and buyout possibilities than either HemaX or dCellVax at this time.

AIMO

Pax.

Now I shall return to my silence and wait for the play to unfold, at least now with a little bit more hope that this time it will be real and successful and not another trick play.

I agree with T & C Ichim on board as employees, able to dedicate their full time to research and development as a "job", the probability of Koos playing games here is greatly diminished.

While Wei-Ping Min is also a very important player, his name pops up all over the place and he gets no income from RGBP until approvals, so how much time he spends on this has been unknown.

The fact Drs. Thomas and Christine Ichim agreed to become employees under Koos at this time I believe is significant both because of their past and their character.

Todd C. is probably on board now (also employed) to work full time on getting the word and value out and making a deal or raising outside funds so Koos won't have to dilute to his eyeballs to move this forward.

The fact that we have officially gone from a company of 1-Koos to 4 employees that can now be working full time for RGBP is a very significant and hopeful sign that something concrete is in the future.

It's actually a company with employees! Imagine that.

Is 2015 a New Case for Hope?

Decided to go back and reread 2015 PRs to see if I could piece together a valid case for hope and that the buzz and buildup to divvy date does not end up the same as the RGBP spinoff (that was supposed to be above a dollar, remember?) And it is encouraging to see that price is sustaining and growing after last PR - could it be this it not another false alarm?

Here's about the best case scenario I can build that is not complete fantasy:
[First, everyone should read this article giving some personal background on Dr. Christine Ichim because I think she is now a major player in what is taking place, posted back in Dec by 1-eye-jack (interestingly enough): Why Dr Thomas Ichim and sister Dr. Christine Ichim are so motivated ].

Jan 8, 2015 PR mentions 2nd Generation of gene silencing drug candidate directed at NR2F6, a treatment that leads cancer cells to change into non cancerous cells: "The findings of novel candidate sequences to improve gene silencing of NR2F6 is a fundamental advancement in our work towards biologically treating cancer," said Dr. Thomas Ichim, Chief Scientific Officer. "Given that Regen BioPharma is already clinically developing gene-silencing therapeutics in its IND for dCellVax, we anticipate substantial synergy of these programs."

Jan 14, 2015 PR giving overview of 2015 priorities talks first about this new treatment candidate (not dCellVax or HemaX), then mentions dCellVax and says HemaXellerate protocols are still under review by FDA for conducting an additional GLP safety study.

Jan 22, 2015 PR - One week later we have the 8K filed to hire both Ichims (Thomas and Christine) with monthly salary and stock (even though RGBP doesn't have the cash). Ergo, I see another confirmation that NR2F6 is now the main focus since its small molecule inhibitors and such have proved effective in similar clinical treatments for a different cancer at success rates over 80% cfr notation in Jan 14th PR. And Christine is the person who has been working and developing this treatment. (Previously she was working on cancer cure for dogs under Entest, so to move her into RGBP and purchase her treatment patents is a clear new direction for RGBP.

Feb 9, 2015 8K tells us RGBP issues promissory Note for $50,000 (not a huge amount, but enough to cover new salaries for a couple months).

Feb 13, 2015 A few days later Todd Caven becomes CFO (whose background is supposed to be in securing funds / mergers).

Feb 17, 2015 Another 8K confirming the issuance of shares to all new hires.

Feb 24, 2015 PR to comment on Flexus buyout as validation of RGBP's own patents and treatments in development. Trying to generate interest of investors and money needed to develop - i.e. Todd Cavens job.

Feb 24, 2015 PR Piggy back PR stating issuance of dividend to shareholders of March 10 of Series A preferred (voting value and future dividend value)


So what to make of these many PRs in succession after our usual long periods of silence? Here are possible scenarios:

1. Worst case - annual bluff to drive up price at least for a few days if Koos and Company have a scam to make money by shorting it or somehow else where SEC does not see it. (Conspiracy theorists and basher bait)

2. Company has been rather stagnated and hoping new hires and people will help to start bringing the company forward. (No major news around the corner, just starting the process of regular updates to act like a real business)

3. RGBP is about to turn the corner with the new NR2F6 breakthrough and has had interest and guarantees of some kind of partnership to fund not only NR2F6, but advance dCellVax and HemaX as well.

4. BEST case scenario: RGBP has finally received word that HemaX protocol for safety trials will be approved, dCellVax will also get Green Light and the development of NR2F6 is so positive, that they are positioning themselves against an outright takeover and setting structure for an advantageous partnership once the news of these 3 developments all hit at once.


I don't know which is the more probable, but I think the recent actions are more focused on NR2F6 holding the brightest future of development and buyout possibilities than either HemaX or dCellVax at this time.

AIMO

Pax.

Now I shall return to my silence and wait for the play to unfold, at least now with a little bit more hope that this time it will be real and successful and not another trick play.

The proof will be in the pudding.

The purchase of Flexus for the amount paid is very encouraging, but we must also admit RGBP is not Flexus in personnel, previous investment funding nor objective success. In 2 years, they have objectively had more success than Koos/BMSN/RGBP since its inception.

While my hope is that RGBP will/can turn the corner, I no longer expect it is imminent, since we know quite a bit from the past and delays and PRs that Koos has not been able to get approval or succeed on any deadline or time frame yet.

Last year's spinoff of RGBP was highly anticipated as the defining point of establishing a company with low amount of stocks issued right before the approval and launch of both HemaXellerate I and then dCellVax to follow and we were to launch into dollar land. I actually had high hopes and put most of my investment money on those long term hopes.

Unfortunately, those of us who've been here the past 2 years no the bitter outcome of that. 2/3rds approval when 3/3rds are needed. HemaXellerate I is not near FDA clinical approval. LET IT BE CLEAR - the PRs confirm that Koos and RGBP have not even come to an understanding with the FDA (or the FDA has told RGBP something they can't accomplish) as to the standards and protocol for safety experiments needed for HemaXellerate I to be done and data submitted before FDA can review for clinical approval. MONTHS have passed with the safety protocol still up in the air.

Put 2 years since IND submittal for HemaXellerate I against Flexus 2 years in existence with one drug in actual clinical trials and 2nd drug anticipated to enter clinical trials this year and you will see the difference and reason why RGBP has a long way to go to be valued anywhere near Flexus.

RGBP would easily double from here if we just got confirmation that RGBP was to proceed with safety trials for HemaXellerate. But basically, RGBP ran out of money at the end of last year when HemaX didn't get the expected approval and from what we know, it is no further along today than it was 4 months ago.

Instead, we are now hoping dCellVax goes somewhere, but the RGBP PR released on that in previous months stated that dCellVax was expected to have to go through the same timeframe as HemaXellerate (i.e., no time soon since the experiments for dCellVax where most likely not done in the GLP lab just like HemaX and therefore more experiments will most likely be needed which means more months to wait).

The only real hope I see of this changing is that someone sees real value in the patents and in Wei-Ping Min and in spite of Koos, is willing to make a deal to take over the patents and proceed with the experiments and implement the plan Koos has no money for.

Traz,
From the reading of the 10Q, the series A preferred (authorized, not yet issued) gives extra voting rights, possible divvy rights and preferred treatment upon liquidation (hopefully not forthcoming).

Will these shares have any trading value or assigned value?

And here is brief history:

[Koos PR shows upside and downside of RGBP - while science seems great, this company comes on scene in 2013, raises 38 million dollars, consists of 6 key people and already lands a deal with larger biopharma. Koos has been a one man show with an unsuccessful history and floats names outside. In two years of filing INDs, has not gotten a green light and we have no assurance of ever getting to clinical trials.]

But Flexus is a different story with one treatment already in clinical trials and prepping for second, all under two years of existence.

Founded in 2013, Flexus is a biotechnology company focused on the creation, development and commercialization of novel anti-cancer therapeutics. Toward this end, the company is leveraging unexploited insights in immunology to discover Agents for Reversal of Tumor Immunosuppression (ARTIS). This disruptive approach to cancer therapy targets that which is common to all tumors, the host immune system.

In contrast to conventional approaches, ARTIS:

Target pathways relevant to many tumor types
Enable the inherent ability of the immune system to destroy tumor cells
Diminish tumor options for escape
Enable broad patient response

Located in San Carlos, CA and funded by blue-chip investors including Kleiner Perkins Caufield and Byers (KPCB), The Column Group (TCG) and Celgene, Flexus has assembled a leadership team with a proven track record of success and an advisory group and team of scientists with unparalleled knowledge and deep expertise in the scientific, drug discovery and translational areas essential to execute on this approach.

Thanks for the original link, GM.

I read the same section before seeing MrMando's post. Makes me wonder if this prolonged delay of the FDA review of HemaXellerate I safety protocols are directly dependent on the FDA finalizing these rules and regs.

On the one side, that might mean further delay of month's on HemaX (thus the new focus on dCellVax and other new Ichim approaches).

On the other side, at least we now have a possible reason for the extended delay, which may mean HemaXellerate I is not dead, but only on hold.

Thanks again for these types of informational posts. New information is very helpful. I admit I'm tired and short tempered with the "to the moon" type comments after any and every PR.

Note Date of Patent filing: August 2013. This patent and explanation was the great hope of BMSN (back then) skyrocketing and the beginning of great things to happen. Clinical trials for HemaX I where orginally projected to have been completed by now. Instead, safety trials needed for final FDA approval to go to clinical trials have not commenced.

So, while the patent publication is good news, it's not propelling us anywhere until we move towards trials.

GM and Trazbull, based on what is the sudden vision of great advancement in RGBP, just because Koos hires himself and a friend and his job description is to follow the board's directives, i.e. himself?

I really thought the spinoff of RGBP shares was the sign FDA clinical approval was imminent, but the last news on Hema was that they haven't started the necessary safety trials yet and no update on DCellVax for months.

So we get news that
1. Koos expands the shares from 50M to a possible 500M (allowing for 10x dilution)
2. Koos hires himself and pays himself 9M shares plus monthly salary with no company income
3. Koos hires Ichim who was already supposed to be part of company
4. Koos hires outsider (maybe to raise funds)

And based solely on PRs of share dilution and hiring of people with no money, the board lights up that somehow we are near approval, after months of indicators that Koos has made no progress in getting Hema to clinical trials and his PR that mentioned DCellVax was that the company anticipated similar timeframe for that as HemaX.

So what am I missing here?

I'm not a CPA and so this is not legal advice, but I would not delete them because all 1099 info is electronically transferred to gov and can be used to match up against your return.

It appears on my 1099 as a dividend (dividends are treated differently than buying/selling stock). As you and Trazbull have pointed out, the Dividend should be Tax Free income because of spinoff so you have to find the right category to apply to the dividend that makes it tax free. Haven't done my taxes yet, so don't have a direct answer.

But like other forms of income that are tax free (Life insurance payment, inheritance, Soc Sec), you still have to declare it on your tax return or your risk of being audited increases.

Don't hold your breath for breakthrough news. Look at the recent financials. In the Qtr ending Dec 2014, a little over $2,000 was spent on research and development - ONLY $2,000, and still awaiting feedback from FDA on agreement of how to conduct safety experiments for HemaXellerate I, i.e. no progress.

The PR on dCellVax progress was that it would need similar safety trials before approval, of which we have heard zilch.

So now they hire someone else a $13,500/month or almost 20x the rate they do research. Wow, that's going to help. Well, it will help if he can raise enough funds to cover his own salary plus some money to do the experiments they need to get any green light to proceed.

I wasted my time and money on this stock over the past 2 years.

Buyers beware. Until something concrete is released (and we've had nothing in the past 5 months) as to real progress, this is going nowhere but down.